{"filing":{"accession_number":"0001213900-26-073709","cik":"0001176309","ticker":"ORMP","company_name":"ORAMED PHARMACEUTICALS INC.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"ea0296520-8k_oramed.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026073709/ea0296520-8k_oramed.htm"},"events":[{"id":15097,"run_id":13465,"accession_number":"0001213900-26-073709","anchor_item_number":"8.01","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The disclosure describes an extension agreement with Scilex regarding outstanding debt obligations totaling approximately $36.2 million (Tranche A Note ~$29.5M + Tranche B Note ~$6.7M). The extension restructures payment terms with a new due date of September 30, 2026, and includes a contingency provision allowing Scilex to satisfy remaining obligations through equity issuance if cash payment fails. This is a material financial event involving debt restructuring and potential dilutive equity issuance, but does not fit the specific categories of debt_issuance (no new debt created), covenant_breach (no breach alleged), or dilutive_issuance (equity issuance is contingent, not immediate). The event is clearly financial in nature and material to investors assessing the company's receivables and capital structure.","company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12732,"accession_number":"0001213900-26-073709","item_number":"8.01","item_title":"Other","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The disclosure describes an extension agreement with Scilex regarding outstanding debt obligations totaling approximately $36.2 million (Tranche A Note ~$29.5M + Tranche B Note ~$6.7M). The extension restructures payment terms with a new due date of September 30, 2026, and includes a contingency provision allowing Scilex to satisfy remaining obligations through equity issuance if cash payment fails. This is a material financial event involving debt restructuring and potential dilutive equity issuance, but does not fit the specific categories of debt_issuance (no new debt created), covenant_breach (no breach alleged), or dilutive_issuance (equity issuance is contingent, not immediate). The event is clearly financial in nature and material to investors assessing the company's receivables and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:25:33.615371+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12732,"accession_number":"0001213900-26-073709","item_number":"8.01","item_title":"Other","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The disclosure describes an extension agreement with Scilex regarding outstanding debt obligations totaling approximately $36.2 million (Tranche A Note ~$29.5M + Tranche B Note ~$6.7M). The extension restructures payment terms with a new due date of September 30, 2026, and includes a contingency provision allowing Scilex to satisfy remaining obligations through equity issuance if cash payment fails. This is a material financial event involving debt restructuring and potential dilutive equity issuance, but does not fit the specific categories of debt_issuance (no new debt created), covenant_breach (no breach alleged), or dilutive_issuance (equity issuance is contingent, not immediate). The event is clearly financial in nature and material to investors assessing the company's receivables and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:25:33.615371+00:00","company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","filing_date":"2026-06-30"}]}